Syndax Pharmaceuticals (SNDX) Misses Q3 EPS by 13c

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q3 EPS of ($0.84), $0.13 worse than the analyst estimate of ($0.71). Revenue for the quarter came in at $305 thousand versus the consensus estimate of $100 thousand.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Chagee Holdings (CHA) Tops Q2 EPS by 3c
• Elastic N.V. (ESTC) Tops Q1 EPS by 12c, Beats on Revenue; offers FY27 Guidance